P.1.g.052 Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed in studies of the SERT Met172 mouse

Nackenoff, Alex; Simmler, Linda D.; Baganz, Nicole L.; Paffenroth, Krista C.; Stanwood, Gregg D.; Pehrson, Alan L.; Sanchéz, Connie; Blakely, Randy D.

doi:10.1016/s0924-977x(15)30305-9

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examples are vortioxetine and vilazodone, which target 5-HT 3 , 5-HT 7 , and 5-HT 1D receptors and 5-HT 1A receptors, respectively . Recent studies have provided evidence that vortioxetine does bind to SERT, where it exhibits the classical SSRI activity of blocking 5-HT reuptake. , However, work from within the Blakely lab with rodent models suggests that the antidepressant efficacy of vortioxetine may not require the blockade of SERT function . An alternative strategy to serotonergic polypharmacy is the targeting of regulatory pathways that control SERT, which as we will discuss below, involves inflammatory cytokine signaling pathways.…”

Section: Evidence Of Immune Activation In Major Depressive Disordermentioning

confidence: 99%

Immune System Activation and Depression: Roles of Serotonin in the Central Nervous System and Periphery

Robson

Quinlan

Blakely

2017

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Serotonin (5-hydroxytryptamine, 5-HT) has long been recognized as a key contributor to the regulation of mood and anxiety and is strongly associated with the etiology of major depressive disorder (MDD). Although more known for its roles within the central nervous system (CNS), 5-HT is recognized to modulate several key aspects of immune system function that may contribute to the development of MDD. Copious amounts of research have outlined a connection between alterations in immune system function, inflammation status, and MDD. Supporting this connection, peripheral immune activation results in changes in the function and/or expression of many components of 5-HT signaling that are associated with depressive-like phenotypes. How 5-HT is utilized by the immune system to effect CNS function and ultimately behaviors related to depression is still not well understood. This Review summarizes the evidence that immune system alterations related to depression affect CNS 5-HT signaling that can alter MDD-relevant behaviors and that 5-HT regulates immune system signaling within the CNS and periphery. We suggest that targeting the interrelationships between immune and 5-HT signaling may provide more effective treatments for subsets of those suffering from inflammation-associated MDD.

show abstract

Section: Evidence Of Immune Activation In Major Depressive Disordermentioning

confidence: 99%

Immune System Activation and Depression: Roles of Serotonin in the Central Nervous System and Periphery

Robson

Quinlan

Blakely

2017

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression

et al. 2016

View full text Add to dashboard Cite

show abstract

Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response

Papakostas

Nielsen

Dragheim

et al. 2018

Journal of Psychiatric Research

View full text Add to dashboard Cite

show abstract

P.1.g.052 Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed in studies of the SERT Met172 mouse

Cited by 3 publications

References 0 publications

Immune System Activation and Depression: Roles of Serotonin in the Central Nervous System and Periphery

Immune System Activation and Depression: Roles of Serotonin in the Central Nervous System and Periphery

Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression

Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response

Contact Info

Product

Resources

About